Ceftazidime/Sulbactam sodium

Tier C — Watch / trade

Xiangbei Welman Pharmaceutical Co., Ltd.

Originator

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：PBPs, Beta Lactamase

Indications (approved)：Pneumonia, Chronic bronchitis, Chronic obstructive pulmonary disease, Urinary tract infection, Pyelonephritis, 支气管肥大症, Bronchitis, Bacterial infection

Regional status

China

Phase II

2013-10-30

Japan

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Ceftazidime/Sulbactam sodium?

Approved indications include: Pneumonia, Chronic bronchitis, Chronic obstructive pulmonary disease, Urinary tract infection, Pyelonephritis, 支气管肥大症, Bronchitis, Bacterial infection.

When does the Ceftazidime/Sulbactam sodium patent expire?

No public expiry year is available for Ceftazidime/Sulbactam sodium yet; this page updates once verified.

How do I get a quote for Ceftazidime/Sulbactam sodium intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-13